Education
About Us
Working with TipRanks
Follow Us
Werewolf Therapeutics (HOWL)
NASDAQ:HOWL
HOWL Stock Chart & Stats
$0.63
-$0.04(-2.90%)
At close: 4:00 PM EST
$0.63
-$0.04(-2.90%)
Day’s Range― - ―
52-Week Range$0.56 - $2.38
Previous CloseN/A
Volume113.58K
Average Volume (3M)1.22M
Market Cap
$30.59M
Enterprise Value$8.58M
Total Cash (Recent Filing)$65.71M
Total Debt (Recent Filing)$37.30M
Price to Earnings (P/E)―
Beta1.92
Next Earnings
Mar 19, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding48,540,200
10 Day Avg. Volume1,746,006
30 Day Avg. Volume1,221,642
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.87
Price to Sales (P/S)34.02
P/FCF Ratio-1.14
Enterprise Value/Market Cap0.28
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.31
Enterprise Value/Ebitda-0.13
Forecast
1Y Price Target
$4.00Price Target Upside534.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Business Development PotentialDirect read-throughs and emerging interest in both WTX-124 and ’330 increase the likelihood of strategic partnerships that could accelerate development and provide non-dilutive funding.
Clinical Efficacy And SafetyWTX-124 produced objective responses in heavily pretreated advanced melanoma patients and showed a favorable tolerability profile without vascular leak syndrome or recurrence of prior immune-related adverse events, supporting clinical potential.
Masking Platform ValidationPositive clinical updates validate the masking platform's ability to enable safer, systemically deliverable therapies, increasing confidence in platform-led pipeline expansion.
Bears Say
Combination Program UncertaintyLack of clear clinical and regulatory insights for the ’124/PD-1 combination raises the risk of needing additional studies or regulatory clarification before a defined approval pathway exists.
Investor Communication RiskConfusion around combination outcomes and incomplete disclosure of results may erode investor confidence and prompt questions about management communication.
Market Reaction And VolatilityShares fell about 40% as investors reacted to limited clinical and regulatory detail on the ’124/PD-1 combination, underscoring susceptibility to abrupt sentiment-driven price swings.
Werewolf Therapeutics News
HOWL FAQ
What was Werewolf Therapeutics’s price range in the past 12 months?
Werewolf Therapeutics lowest stock price was $0.56 and its highest was $2.38 in the past 12 months.
What is Werewolf Therapeutics’s market cap?
Werewolf Therapeutics’s market cap is $30.59M.
When is Werewolf Therapeutics’s upcoming earnings report date?
Werewolf Therapeutics’s upcoming earnings report date is Mar 19, 2026 which is in 67 days.
How were Werewolf Therapeutics’s earnings last quarter?
Werewolf Therapeutics released its earnings results on Nov 04, 2025. The company reported -$0.36 earnings per share for the quarter, beating the consensus estimate of -$0.383 by $0.023.
Is Werewolf Therapeutics overvalued?
According to Wall Street analysts Werewolf Therapeutics’s price is currently Undervalued.
Does Werewolf Therapeutics pay dividends?
Werewolf Therapeutics does not currently pay dividends.
What is Werewolf Therapeutics’s EPS estimate?
Werewolf Therapeutics’s EPS estimate is -0.35.
How many shares outstanding does Werewolf Therapeutics have?
Werewolf Therapeutics has 48,540,200 shares outstanding.
What happened to Werewolf Therapeutics’s price movement after its last earnings report?
Werewolf Therapeutics reported an EPS of -$0.36 in its last earnings report, beating expectations of -$0.383. Following the earnings report the stock price went down -7.634%.
Which hedge fund is a major shareholder of Werewolf Therapeutics?
Currently, no hedge funds are holding shares in HOWL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Werewolf Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (534.92% Upside)
$4.00 (534.92% Upside)
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.95%
12-Months-Change
Fundamentals
Return on Equity
-122.43%
Trailing 12-Months
Asset Growth
-39.78%
Trailing 12-Months
Company Description
Werewolf Therapeutics
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
HOWL Stock 12 Month Forecast
Average Price Target
$4.00
▲(534.92% Upside)
Technical Analysis
CervoMed
―
NRX Pharmaceuticals
―
Kalaris Therapeutics
―
Coeptis Therapeutics Holdings
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
43.55% Insiders
3.29% Mutual Funds
31.93% Other Institutional Investors
18.71% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---